Merck & Co. (MRK)
(Delayed Data from NYSE)
$102.92 USD
+1.75 (1.73%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $103.13 +0.21 (0.20%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Merck (MRK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$135.92 | $168.00 | $110.00 | 34.35% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Merck comes to $135.92. The forecasts range from a low of $110.00 to a high of $168.00. The average price target represents an increase of 34.35% from the last closing price of $101.17.
Analyst Price Targets (24)
Broker Rating
Merck currently has an average brokerage recommendation (ABR) of 1.30 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms. The current ABR compares to an ABR of 1.23 a month ago based on 26 recommendations.
Of the 27 recommendations deriving the current ABR, 23 are Strong Buy, representing 85.19% of all recommendations. A month ago, Strong Buy represented 88.46%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 23 | 23 | 23 | 23 | 23 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.30 | 1.30 | 1.23 | 1.23 | 1.23 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
11/6/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
11/1/2024 | Wells Fargo Securities | Mohit Bansal | Hold | Hold |
11/1/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
10/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/17/2024 | Not Identified | Not Identified | Not Available | Hold |
10/14/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
10/8/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
10/7/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
9/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/16/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
9/11/2024 | UBS | Trung Huynh | Not Available | Strong Buy |
9/8/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
8/13/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/8/2024 | Berenberg Bank | Luisa Hector | Strong Buy | Strong Buy |
8/6/2024 | Daiwa America | Narumi Nakagiri | Strong Buy | Strong Buy |
7/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/31/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
7/30/2024 | Evercore Partners | Umer Raffat | Not Available | Strong Buy |
7/16/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
6/5/2024 | Argus Research Corp. | Jasper Hellweg | Not Available | Strong Buy |
6/5/2024 | Not Identified | Not Identified | Hold | Hold |
5/15/2024 | Atlantic Equities | Steven K Chesney | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.30 |
ABR (Last week) | 1.30 |
# of Recs in ABR | 27 |
Average Target Price | $135.33 |
LT Growth Rate | 9.00% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 57 of 252 |
Current Quarter EPS Est: | 1.90 |
MRK FAQs
Merck & Co., Inc. (MRK) currently has an average brokerage recommendation (ABR) of 1.30 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms.
The average price target for Merck & Co., Inc. (MRK) is $135.33. The current on short-term price targets is based on 10 reports.
The forecasts for Merck & Co., Inc. (MRK) range from a low of $110 to a high of $168. The average price target represents a increase of $31.49 from the last closing price of $102.92.
The current UPSIDE for Merck & Co., Inc. (MRK) is 31.49%
Based on short-term price targets offered by 24 analysts, the average price target for Merck comes to $135.92. The forecasts range from a low of $110.00 to a high of $168.00. The average price target represents an increase of 34.35% from the last closing price of $101.17.